Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04210128 · ClinicalTrials.gov registry record

Glucose Monitoring to Predict and Treat High Glucose Levels After Steroid Treatment

A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
3
Enrollment target

NCT04210128: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.

NCT04210128 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT04210128 has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
3 participants
Enrollment target

Study Summary

The purpose of this study is to see if continuous glucose monitoring can identify how often people who have pre-diabetes or medical obesity or well-controlled diabetes experience very high glucose values while receiving chemotherapy for breast cancer or pancreatic.

Primary Outcome

glucose \> 400 mg/dL for over 3 contiguous hours

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2019-12-20
Est. Completion 2023-10-31
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the finished NCT04210128 record still lists

NCT04210128 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 3 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT04210128 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04210128 about?

NCT04210128 is a clinical study titled "Glucose Monitoring to Predict and Treat High Glucose Levels After Steroid Treatment". The purpose of this study is to see if continuous glucose monitoring can identify how often people who have pre-diabetes or medical obesity or well-controlled diabetes experience very high glucose values while receiving chemotherapy for breast cancer or pancreatic.

What is the current status of trial NCT04210128?

This trial is currently completed. The enrollment target is 3 participants. The study started on 2019-12-20. Estimated completion is 2023-10-31.

Who is sponsoring clinical trial NCT04210128?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04210128, the US trial registry maintained by the National Library of Medicine. NCT04210128 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.